EXHIBIT 3.6

                           CERTIFICATE OF AMENDMENT OF
         AMENDED CERTIFICATE OF DESIGNATION, PREFERENCES, AND RIGHTS OF
                     SERIES C CONVERTIBLE PREFERRED STOCK OF
                           MOLECULAR DIAGNOSTICS, INC.
                    (PURSUANT TO SECTIONS 151 AND 242 OF THE
                        DELAWARE GENERAL CORPORATION LAW)

         MOLECULAR DIAGNOSTICS, INC., a corporation organized and existing under
and by virtue of the General Corporation Law of the State of Delaware (the
"Corporation"), DOES HEREBY CERTIFY:

         FIRST, that the Certificate of Designation be amended in Article First
by reducing the number of shares designated as Series C Preferred Stock from
1,800,000 to 1,666,666.

         SECOND, that the Certificate of Designation be amended in paragraph A
of Article Second by reducing the stated value from $4.50 to $3.00.

         THIRD, that the Certificate of Designation be amended by deleting in
its entirety paragraph A of Article Sixth and substituting in lieu thereof the
following:
                  (A) Each share of the Series C Preferred Stock shall be
         convertible, at the option of the respective holders thereof, at any
         time after the date of issuance, at the office of any transfer agent
         for the Series C Preferred Stock, or if there is none, then at the
         office of the transfer agent for the Common Stock, or if there is no
         such transfer agent, at the principal executive office of the Company,
         into that number of shares of Common Stock of the Company equal to the
         Stated Value divided by the conversion price in effect at the time of
         conversion (the "Conversion Price"). The Conversion Price shall be
         $0.60 per share, subject to antidilution adjustments. The number of
         shares of Common Stock into which each share of Series C Preferred
         Stock is convertible is hereinafter collectively referred to as the
         "Conversion Rate."

         FOURTH, that the Certificate of Designation be amended by deleting in
its entirety paragraph B of Article Sixth.




         FIFTH, that this amendment to the Certificate of Designation was duly
adopted in accordance with the provisions of Sections 151 and 242 of the General
Corporation Law of the State of Delaware.

         IN WITNESS WHEREOF, MOLECULAR DIAGNOSTICS, INC. has caused this
Certificate to be executed by Leonard R. Prange of the Corporation this 19th day
of November, 2001.

                                       MOLECULAR DIAGNOSTICS, INC.


                                       By: /s/ Leonard R. Prange
                                               Leonard R. Prange
                                               President